Bind founders publish data showing nanomed transport ability

The cofounders of Bind Therapeutics ($BIND), which include MIT professor and entrepreneur Robert Langer, published new data for its targeted nanoparticle platform called Accurins, which are designed to carry drugs to specific parts of the body to treat diseases. The paper, published in the journal Science Translational Medicine, shows the nanoparticles' ability to cross biological barriers including the intestinal epithelial barrier, the pulmonary epithelial barrier, the blood-brain barrier, the fetal-placental barrier and the blood-ocular barrier. "The current findings are expected to significantly broaden the reach of our platform and present opportunities to non-invasively administer Accurins of large molecular weight drugs, such as proteins and RNA, for a myriad of human diseases," said Bind president and CEO Scott Minick in a statement. Release

Suggested Articles

Researchers in the U.K. have developed a technique to better predict results in liver cancer when drug-laden polymer beads are used to deliver medicines.

Researchers at Johns Hopkins have changed the structure of a new cancer drug to allow it to more easily pass the blood-brain barrier, giving it access to…

Medtronic’s world-first FDA-approved hybrid closed-loop insulin delivery system might soon face competition, as T1D Exchange has pledged to invest in the…